From major journals, first or last author from the Institute for Cancer Research
IUIS 2023: yEFIS workshop on career development and code-switching
Eur J Immunol, e2451155 (in press)
DOI 10.1002/eji.202451155, PubMed 38676471
An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer
Mol Oncol (in press)
DOI 10.1002/1878-0261.13656, PubMed 38671580
Engineering immune-evasive allogeneic cellular immunotherapies
Nat Rev Immunol (in press)
DOI 10.1038/s41577-024-01022-8, PubMed 38658708